Skip to main content
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 2013 Dec 5;2013:960769. doi: 10.1155/2013/960769

Chlamydia trachomatis Infection in HIV-Infected Women: Need for Screening by a Sensitive and Specific Test

Sonali Bhattar 1, Preena Bhalla 1,*, Sanjim Chadha 1, Reva Tripathi 2, Ravinder Kaur 1, Kabir Sardana 3
PMCID: PMC3870114  PMID: 24382941

Abstract

Reproductive tract infection (RTIs)/sexually transmitted infections (STIs) are recognized as a major public health problem, particularly due to their relationship with HIV infection. Early detection and treatment of Chlamydia trachomatis infection (CTI) among HIV-infected and HIV-uninfected women may impact heterosexual HIV transmission. A total of 120 participants were enrolled: 30 HIV seropositive women with symptoms of RTIs, 30 HIV seropositive women without symptoms of RTIs, 30 HIV seronegative women with symptoms of RTIs, and 30 HIV seronegative women without symptoms of RTIs. One endocervical swab was collected from all participants and CTI was detected by real-time PCR (COBAS TaqMan CT Test, v2.0). CTI was detected in 4 (6.67%) HIV-infected women and in 1 (1.67%) HIV-uninfected woman (OR 4.214; 95% CI 0.457–38.865). Vaginal discharge was present in almost half of HIV-infected and HIV-uninfected women; lower abdominal pain was present in 11 (18.3%) of HIV-infected and in 9 (15%) of HIV-uninfected women. This study showed that CTI is more prevalent among HIV-infected females as compared to HIV-uninfected females. As the use of real-time PCR is not feasible in most hospitals, efforts should be made to develop a simple, sensitive, and specific test to identify women with CTI for prevention of sequelae and HIV transmission.

1. Introduction

Genital infection due to Chlamydia trachomatis is one of the most prevalent bacterial sexually transmitted infections (STIs) [1]. According to the WHO estimates, globally 92 million new cases of C. trachomatis infection occur each year and about two-thirds of these cases occur in the developing world, where diagnostic and treatment services are scarce [2, 3]. Most epidemiological data on Chlamydia trachomatis infection (CTI) is from industrialized nations and reliable data from the resource poor developing nations is not available where the disease burden is concentrated. However, it is important to document laboratory-confirmed incidence and prevalence of CTI from the developing world as well. The available Indian data show a wide variation in CT prevalence with infection rates in Indian women ranging from 3.3% to 33% depending on the population sampled [413].

Infection with this agent is usually asymptomatic in up to 80% of women which makes diagnosis and detection all the more difficult. Left undetected and untreated the infection may evolve into pelvic inflammatory disease and may result in serious sequelae, such as ectopic pregnancy and infertility [14, 15]. CTI in women has also been linked to adverse pregnancy outcomes like recurrent miscarriage and preterm labor and may cause conjunctivitis, nasopharyngitis, and pneumonia in newborns by vertical transmission [3]. Because the infection is easily treatable with antibiotics, early detection and treatment of infected individuals are the key to prevent adverse sequelae among those infected and reduce C. trachomatis transmission [16]. Thus, it is important to screen adolescents and sexually active women for CTI even if they are asymptomatic [17, 18]. But, in the developing countries with the exception of sporadic testing, screening for Chlamydia is rarely done.

Epidemiological studies have also shown that untreated genital Chlamydia infection can lead to an increased risk for heterosexual acquisition of HIV. Hence, screening for CTI done in high risk populations can assist in designing HIV risk reduction strategies [8]. On the other hand, immunosuppression due to HIV may lead to more aggressive Chlamydia disease conditions like PID in HIV seropositive women. Thus, screening for CTI in HIV seropositive women is highly recommended to prevent morbidity associated with the disease and devastating clinical consequences [19].

Different diagnostic modalities for detection of CTI like serology, culture method, ELISA for antigen and antibody, direct fluorescence assay (DFA) and nucleic acid amplification tests (NAATs) have been used in the last 20 years but none of them are 100% sensitive. Each has its own limitations [14]. Table 1 shows the prevalence of CTI detected by using different diagnostic techniques in New Delhi population.

Table 1.

Diagnostic methods for CTI.

Year Study population Tissue culture DFA ELISA for antigen ELISA for antibody PCR RT PCR Ref. no.
1993 Pregnant women 10 IgA 33.3
IgG 44.6
[20]
1999 NGU 43.8 [21]
2001 Community study among women 29.0 [22]
2004 Infant pneumonia 17.0 37.0 55.0 (in-house) [23]
2005 PID and infertility IgG 14
IgM 32
IgA 6.7
[24]

Polymerase chain reaction is an accurate, rapid, and reliable method for the detection of Chlamydia trachomatis [25]. Real-time PCR has increasingly been used and is easier to perform and faster, and since it is performed in a closed system it is less prone to contamination than the conventional PCR [26]. Keeping the above background in mind this study was undertaken to generate reliable data regarding prevalence of CTI in HIV-infected and HIV-uninfected women by real-time PCR, the most sensitive and specific test available currently for diagnosing genital Chlamydia infection. The primary objective of this study was to establish the need for screening HIV seropositive women for CTI.

2. Materials and Methods

2.1. Study Population

Study subjects were recruited as follows:

  1. thirty adult HIV seropositive women with symptoms suggestive of RTIs (study group A1),

  2. thirty adult HIV seropositive women without symptoms suggestive of RTIs (study group A2),

  3. thirty age and sex matched adult HIV seronegative women with symptoms suggestive of RTIs (control group B1),

  4. thirty age and sex matched adult HIV seronegative women without symptoms suggestive of RTIs (control group B2).

All the study subjects were enrolled from the Integrated Counseling and Testing Center (ICTC) for HIV/AIDS, Department of Microbiology, Maulana Azad Medical College, which is attached to the Lok Nayak Hospital, New Delhi.

2.2. Study Design

This study was conducted prospectively between July 2010 and January 2011 at the HIV molecular laboratory of the Department of Microbiology, Maulana Azad Medical College. This was a cross-sectional analysis to determine the prevalence of Chlamydia trachomatis infection by using real-time PCR in HIV seropositive and seronegative, symptomatic, and asymptomatic women visiting the ICTC of our department. Subjects were enrolled in this study following institutional ethical committee clearance and a written informed consent of all participants. Each participant was interviewed using a questionnaire concerning general sociodemographic information, personal details, and clinical symptoms. Subjects having one or more of the following symptoms were considered symptomatic for RTI [27]:

  1. vaginal discharge,

  2. vesicular and/or non­vesicular genital ulcers,

  3. inguinal bubo,

  4. lower abdominal pain,

  5. genital skin conditions,

  6. urinary burning or frequency,

  7. dysmenorrhea, menorrhagia, and intermenstrual bleeding.

Each study subject then underwent a general physical, per abdomen, per speculum, and per vaginum examination.

2.3. Laboratory Methods

Diagnosis of HIV infection was done by following the standard protocol at our ICTC that employs pretest and posttest counseling and obtains informed consent before HIV testing. Three different rapid tests were used to detect HIV-1 and HIV-2 antibodies (COMBAIDS (Span Diagnostics Ltd.), Retrocheck HIV (Qualpro Diagnostics), and Tri-line (Rapid Diagnostics)) following the manufacturer's instructions.

One endocervical swab was collected from all participants according to the instructions provided in the specimen collection and transport kit (AMPLICOR STD swab collection and transport set) for detection of Chlamydia trachomatis by real-time PCR. Genital C. trachomatis infection was diagnosed by using COBAS TaqMan CT Test, v2.0, an in vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis DNA in female endocervical swab specimens. Specimens were processed using the AMPLICOR CT/NG specimen preparation kit for manual specimen preparation and the COBAS TaqMan 48 analyzer for automated amplification and detection (Roche Diagnostics). The test was performed and reading was interpreted as per the kit literature.

2.4. Statistical Analysis

95% confidence interval was tested to ascertain whether the results were statistically significant. Odd ratio was calculated for relative risk determination.

3. Results

A total of 120 participants were enrolled for this study. The age and gender profile of all the participants is shown in Table 2. In both the HIV seropositive study group and the HIV seronegative control group the age group of 26–35 years was the predominant age group. The mean age of HIV-infected cases was found to be 30.92 ± 5.7 years and in HIV-uninfected controls 28.52 ± 6.9 years.

Table 2.

Demographic profile of study participants.

HIV seropositive cases
(n = 60)
HIV seronegative controls
(n = 60)
Age
 18–25 8 (13.3) 23 (38.3)
 26–35 39 (65) 30 (50)
 36–45 12 (20) 6 (10)
 45–49 1 (1.6) 1 (1.6)
Marital status
 Married 48 (80) 59 (98.3)
 Widowed 10 (16.6) 1 (1.67)
 Divorced 2 (3.3) 0 (0)
No. of sexual partners
 1 56 (93.3) 59 (98.3)
 2 3 (5) 1 (1.7)
 ≥3 1 (1.7) 0
Use of barrier contraception
 Yes
  Regular 4 (6.7) 6 (10)
  Infrequent 8 (13.3) 16 (26.7)
 No 48 (80) 38 (63.3)
History of abortion
 Yes 7 (11.6) 4 (6.6)
 No 53 (88.3) 56 (93.3)

Table 3 shows the presenting complaints of the symptomatic women in both the HIV seropositive study group and the HIV seronegative control group. Vaginal discharge and lower abdominal pain were the most common presenting complaints amongst the symptomatic participants.

Table 3.

Complaints among symptomatic subjects (A1 + B1) (N = 60).

Complaints Study group A1
(n = 30) no. (%)
Control group B1
(n = 30) no. (%)
Vaginal discharge 28 (93.33) 27 (90)
Genital ulcer 3 (10) 1 (3.33)
Inguinal swelling 1 (3.33) 0 (0)
Lower abdominal pain 11 (36.66) 9 (30)
Genital warts 2 (6.67) 0 (0)
Itching in external genitalia 5 (16.67) 3 (10)
Intermenstrual bleeding 2 (6.67) 1 (3.33)
Urinary complaints 6 (20) 4 (13.33)
Generalized rashes 2 (6.67) 1 (3.33)
Fever 2 (6.67) 0

Table 4 shows the STI/RTI syndromes diagnosed in study subjects on per speculum examination. Vaginitis was the most common syndrome diagnosed in both the study and the control groups.

Table 4.

STI/RTI syndromes among study subjects on the basis of per speculum examination (N = 120).

Study subjects HIV positive study group
(n = 60) no. (%)
HIV negative control group
(n = 60) no. (%)
Vaginitis 30 (50) 34 (56.67)
Cervicitis 3 (5) 2 (3.33)
Vaginitis + cervicitis 3 (5) 0 (0)
Genital ulcer 2 (3.33) 1 (1.67)
Genital warts 2 (3.33) 0 (0)
NAD* 20 (33.33) 23 (38.33)

Total 60 (100) 60 (100)

*No abnormality detected.

Table 5 shows the correlation between presence of symptoms and CTI in the study and the control groups. Chlamydia trachomatis infection was more commonly diagnosed in the asymptomatic HIV seropositive study subjects as compared to the symptomatic HIV seropositive study subjects.

Table 5.

Correlation between symptoms of RTI/STI and CTI.

Symptoms of RTI/STI HIV positive study group (n = 60) HIV negative control group (n = 60) no. (%)
Present
(n = 30) no. (%)
Absent
(n = 30) no. (%)
Present
(n = 30) no. (%)
Absent
(n = 30) no. (%)
Chlamydia trachomatis positive 1 (3.33) 3 (10) 1 (3.33) 0 (0)

In our study the prevalence of CTI was higher in HIV seropositive women as compared to HIV seronegative women (OR 4.214; 95% CI 0.457–38.865) and among the HIV positive asymptomatic as compared to the HIV negative asymptomatic (OR 2.111; 95% CI 1.606–2.776), although the differences were not found to be statistically significant (Table 6).

Table 6.

Correlation between HIV positivity and presence of CTI among women with and without symptoms.

P value Odds ratio (95% CI)
HIV positive (A1 + A2)
versus
HIV negative (B1 + B2)
0.171 4.214
(0.457–38.865)

HIV positive symptomatic (A1)
versus
HIV negative symptomatic (B1)
1 1
(0.060–16.763)

HIV positive asymptomatic (A2)
versus
HIV negative asymptomatic (B2)
0.076 2.111
(1.606–2.776)

4. Discussion

In India STIs/RTIs and HIV/AIDS are major public health problems. Incidence and prevalence data have a key role in control strategies for HIV and STIs. Comprehensive baseline information on the epidemiology of STIs is essential for the design, implementation, and monitoring of successful control programs to reduce their incidence [28]. Routine surveillance of STIs/RTIs is not carried out in our country due to the lack of laboratory diagnostic facilities, limited resources, stigma, and discrimination associated with STIs and poor attendance of STI patients, especially women, in sexually transmitted disease (STD) clinics. Taking the above facts into consideration, it is meaningful to have genuine laboratory-confirmed data on the incidence/prevalence of RTIs/STIs in India [29]. As the asymptomatic nature of STIs [30] is well known, there is a need to adopt a specific strategy for the screening of the sexually active population in India to reduce the overall rate of STIs, which would, in turn, reduce the risk of HIV infection. Our study presents an insight into the prevalence data of genital Chlamydia infections in HIV-infected and HIV-uninfected women visiting the ICTC of New Delhi's largest tertiary care hospital.

The mean age of the HIV seropositive subjects in our study was 30.92 ± 5.7 and that of the HIV seronegative control group was 28.52 ± 6.9. This compares well with the findings of another study done in Baroda, India, to look for the prevalence of RTIs in HIV-infected women wherein the mean age for HIV positive women was 30 and that for HIV negative women was 27 [31]. The predominant age group in the HIV positive participants in our study was 26–35 years. This association of Chlamydia infection with younger age is consistent with studies from other developing countries [32, 33]. This finding supports the fact that young sexually active adults should constitute a priority target group in the STI control program. However, the findings of our study cannot be generalized to all sexually active adults as the study has its limitations of a small sample size and the study participants belonging to a high risk group being recruited from the ICTC of our department. 80% of our HIV positive study participants were married which is quiet similar to what has been reported by another study from sub-Saharan Africa in which 85.3% of the HIV-infected women were married [34]. This finding highlights the importance of concurrently screening and treating spouses/sexual partners to decrease the STI burden in the country but this is challenging due to the lack of knowledge and cooperation from husbands especially in the Indian setup.

In the present study, vaginal discharge and lower abdominal pain were the 2 most frequently reported symptoms by the symptomatic women in both the study and the control groups, confirming the data reported by some previous Indian studies [22, 29]. Another notable observation of our study was that vaginitis was the most common clinical finding detected on per speculum examination in both the HIV positive (50%) and the HIV negative groups (56.67%) which is in accordance with the observations of Garg et al. and Balamurugan and Bendigeri where a majority of women on clinical examination had vaginitis of 94.6% and 36.9%%, respectively [22, 35].

The present study also validates the fact that Chlamydia infections are usually asymptomatic as 10% of the asymptomatic women were diagnosed with CTI while only 3.3% of symptomatic women had lab-confirmed CTI in the HIV positive study group. This finding has been documented by another study done in Canada [36]. Once again this emphasizes the importance of routine screening of at risk young sexually active women.

In our study CTI was detected in 6.67% (4/60) HIV-infected women and in 1.67% (1/60) HIV-uninfected women by real-time PCR although this difference was not statistically significant but the odds ratio was 4.214. A study from Cuba reported C. trachomatis infection in 10% of HIV-infected cases and 6.6% of HIV-uninfected cases by nested PCR but the difference was not statistically significant while the Odds ratio was 3.39 which is in concordance with our study [37]. Studies conducted by Natividad-Villanueva et al. in USA and Seck et al. in Senegal reported C. trachomatis infection in 3.33% and 2.1% of HIV-infected females, respectively [38, 39]. Larger studies are required to validate our observation as our study was restricted to a small number of cases.

5. Conclusions

This study clearly shows that CTI is more prevalent among HIV-infected females (with or without symptoms of RTI) as compared to HIV-uninfected females. Our study also stresses the usefulness of screening asymptomatic HIV-infected and HIV-uninfected females for CTI by risk assessment and diagnostic testing periodically to prevent the occurrence of adverse outcomes associated with the disease and also to check further spread of infection in the community. For countries like India that still do not currently have an active Chlamydia screening program in place, randomized controlled trials are required to delineate the benefits of screening in the sexually active population as our study participants represent a high risk group. It is also important that any test adopted in a national screening program be used in the primary care setting by practitioners without the need for expensive training and equipment. However, since use of real-time PCR is not feasible in most hospitals in developing countries efforts should be made to develop a simple, cost-effective, sensitive, and specific point of care test to identify and treat women with CTI for prevention of sequelae and HIV transmission.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

The authors would like to thank the technical assistance provided by Mrs. Sujatha Grover and Mrs. Seema Malhotra.

References

  • 1.World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections-overviewed and estimates. WHO/CDS/CSR/EDC/2001.10, 2001.
  • 2.Patel AL, Sachdev D, Nagpal P, et al. Prevalence of Chlamydia infection among women visiting a gynaecology outpatient department: evaluation of an in-house PCR assay for detection of Chlamydia trachomatis . Annals of Clinical Microbiology and Antimicrobials. 2010;9, article 24 doi: 10.1186/1476-0711-9-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Land JA, van Bergen JEAM, Morré SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Human Reproduction Update. 2009;16(2):189–204. doi: 10.1093/humupd/dmp035.dmp035 [DOI] [PubMed] [Google Scholar]
  • 4.Alexander R, Mathai E, Nayyar V, Mathew M, Jasper P. Low prevalence of chlamydial endocervical infection in antenatal South Indian women. Genitourinary Medicine. 1993;69(3):240–241. doi: 10.1136/sti.69.3.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Becker M, Stephen J, Moses S, et al. Etiology and determinants of sexually transmitted infections in Karnataka state, South India. Sexually Transmitted Diseases. 2010;37(3):159–164. doi: 10.1097/OLQ.0b013e3181bd1007. [DOI] [PubMed] [Google Scholar]
  • 6.Brabin L, Gogate A, Gogate S, et al. Reproductive tract infection, gynaecological morbidity and HIV seroprevalence among women in Mumbai, India. Bulletin of the World Health Organization. 1998;76(3):277–287. [PMC free article] [PubMed] [Google Scholar]
  • 7.Joyce AG, Thyagarajan SP, Rajendran P, et al. Chlamydia trachomatis genital infection in apparently healthy adult population of Tamil Nadu, India: a population-based study. International Journal of STD and AIDS. 2004;15(1):51–55. doi: 10.1258/095646204322637272. [DOI] [PubMed] [Google Scholar]
  • 8.Joyee AG, Thyagarajan SP, Reddy EV, Venkatesan C, Ganapathy M. Genital chlamydial infection in STD patients: its relation to HIV infection. Indian Journal of Medical Microbiology. 2005;23(1):37–40. doi: 10.4103/0255-0857.13871. [DOI] [PubMed] [Google Scholar]
  • 9.Malik A, Jain S, Rizvi M, Shukla I, Hakim S. Chlamydia trachomatis infection in women with secondary infertility. Fertility and Sterility. 2009;91(1):91–95. doi: 10.1016/j.fertnstert.2007.05.070. [DOI] [PubMed] [Google Scholar]
  • 10.Mania-Pramanik J, Meherji PK, Gokral JS, Donde UM. Chlamydia trachomatis infection in an urban setting. Sexually Transmitted Infections. 2001;77(2):p. 141. doi: 10.1136/sti.77.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Rastogi S, Das B, Salhan S, Mittal A. Effect of treatment for Chlamydia trachomatis during pregnancy. International Journal of Gynecology and Obstetrics. 2003;80(2):129–137. doi: 10.1016/s0020-7292(02)00371-5. [DOI] [PubMed] [Google Scholar]
  • 12.Singh V, Salhan S, Das BC, Mittal A. Predominance of Chlamydia trachomatis serovars associated with urogenital infections in females in New Delhi, India. Journal of Clinical Microbiology. 2003;41(6):2700–2702. doi: 10.1128/JCM.41.6.2700-2702.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Singh V, Sehgal A, Satyanarayana L, Gupta MM, Parashari A, Chattopadhya D. Clinical presentation of gynecologic infections among Indian women. Obstetrics and Gynecology. 1995;85(2):215–219. doi: 10.1016/0029-7844(94)00367-M. [DOI] [PubMed] [Google Scholar]
  • 14.Mittal V, Agarwal J, Jain A, Verma AK. Prevalence of genital Chlamydia trachomatis in women using PCR on urine specimen. Biomedical Research. 2010;21(3):301–304. [Google Scholar]
  • 15.Gaydos CA, Theodore M, Dalesio N, Wood BJ, Quinn TC. Comparison of three nucleic acid amplification tests for detection of Chlamydia trachomatis in urine specimens. Journal of Clinical Microbiology. 2004;42(7):3041–3045. doi: 10.1128/JCM.42.7.3041-3045.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after chlamydia trachomatis genital infection in women. Journal of Infectious Diseases. 2010;201(supplement 2):S134–S155. doi: 10.1086/652395. [DOI] [PubMed] [Google Scholar]
  • 17.Burstein GR, Gaydos CA, Diener-West M, Howell MR, Zenilman JM, Quinn TC. Incident Chlamydia trachomatis infections among inner-city adolescent females. The Journal of the American Medical Association. 1998;280(6):521–526. doi: 10.1001/jama.280.6.521. [DOI] [PubMed] [Google Scholar]
  • 18.Burstein GR, Waterfield G, Joffe A, Zenilman JM, Quinn TC, Gaydos CA. Screening for gonorrhea and chlamydia by DNA amplification in adolescents attending middle school health centers: oppportunity for early intervention. Sexually Transmitted Diseases. 1998;25(8):395–402. doi: 10.1097/00007435-199809000-00001. [DOI] [PubMed] [Google Scholar]
  • 19.Thomas K, Simms I. Chlamydia trachomatis in subfertile women undergoing uterine instrumentation: how we can help in the avoidance of iatrogenic pelvic inflammatory disease? Human Reproduction. 2002;17(6):1431–1432. doi: 10.1093/humrep/17.6.1431. [DOI] [PubMed] [Google Scholar]
  • 20.Sarin U, Bhalla P, Biswas J. A prospective study of lower genital tract infection by Chlamydia trachomatis in pregnancy. Journal of Obstetrics and Gynecology of India. 1993:342–347. [Google Scholar]
  • 21.Nair D, Bhalla P, Mathur MD. Comparison of enzyme immunoassay and direct fluorescent antibody test for the detection of Chlamydia trachomatis in non gonococcal urethritis. Indian Journal of Medical Microbiology. 1999;17(4):184–186. [Google Scholar]
  • 22.Garg S, Bhalla P, Sharma N, et al. Comparison of self-reported symptoms of gynaecological morbidity with clinical and laboratory diagnosis in a New Delhi slum. Asia-Pacific Population Journal. 2001;16(2):75–92. [Google Scholar]
  • 23.Chawla R, Bhalla P, Sachdev HPS. A pilot study of Chlamydia trachomatis pneumonia in infants. Indian Journal of Medical Microbiology. 2004;22(3):185–188. [PubMed] [Google Scholar]
  • 24.Vidhani S, Mehta S, Bhalla P, Bhalla R, Sharma VK, Batra S. Seroprevalence of Chlamydia trachomatis infection amongst patients with pelvic inflammatory diseases and infertility. Journal of Communicable Diseases. 2005;37(3):233–238. [PubMed] [Google Scholar]
  • 25.Mahony JB, Luinstra KE, Sellors JW, Jang D, Chernesky MA. Confirmatory polymerase chain reaction testing for Chlamydia trachomatis in first-void urine from asymptomatic and symptomatic men. Journal of Clinical Microbiology. 1992;30(9):2241–2245. doi: 10.1128/jcm.30.9.2241-2245.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Jaton K, Bille J, Greub G. A novel real-time PCR to detect Chlamydia trachomatis in first-void urine or genital swabs. Journal of Medical Microbiology. 2006;55(12):1667–1674. doi: 10.1099/jmm.0.46675-0. [DOI] [PubMed] [Google Scholar]
  • 27.Ministry of Health and Family Welfare Government of India. National Guidelines on Prevention, Management and Control of Reproductive Tract Infections Including Sexually Transmitted Infections. NACO; 2007. [Google Scholar]
  • 28.World Health Organization. A new approach to STD control and AIDS prevention. Global AIDS News. 1994;4:13–15. [PubMed] [Google Scholar]
  • 29.Ray K, Bala M, Bhattacharya M, Muralidhar S, Kumari M, Salhan S. Prevalence of RTI/STI agents and HIV infection in symptomatic and asymptomatic women attending peripheral health set-ups in Delhi, India. Epidemiology and Infection. 2008;136(10):1432–1440. doi: 10.1017/S0950268807000088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Nessa K, Waris SA, Alam A, et al. Sexually transmitted infections among brothel-based sex workers in Bangladesh: high prevalence of asymptomatic infection. Sexually Transmitted Diseases. 2005;32(1):13–19. doi: 10.1097/01.olq.0000148298.26228.74. [DOI] [PubMed] [Google Scholar]
  • 31.Sharma A, Marfatia YS, Modi M. Reproductive tract infections in HIV positive women: a case control study. Indian Journal of Sexually Transmitted Diseases and AIDS. 2009;30(1):16–18. doi: 10.4103/2589-0557.55473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Acosta-Cázares B, Ruiz-Maya L, de la Peña JE. Prevalence and risk factors for Chlamydia trachomatis infection in low-income rural and suburban populations of Mexico. Sexually Transmitted Diseases. 1996;23(4):283–288. doi: 10.1097/00007435-199607000-00007. [DOI] [PubMed] [Google Scholar]
  • 33.Miranda AE, Szwarcwald CL, Peres RL, Page-Shafer K. Prevalence and risk behaviors for chlamydial infection in a population-based study of female adolescents in Brazil. Sexually Transmitted Diseases. 2004;31(9):542–546. doi: 10.1097/01.olq.0000137899.25542.75. [DOI] [PubMed] [Google Scholar]
  • 34.Alcaide ML, Jones DL, Chitalu N, Weiss S. Chlamydia and Gonorrhea infections in HIV-positive women in urban Lusaka, Zambia. Journal of Global Infectious Diseases. 2012;4(3):141–144. doi: 10.4103/0974-777X.100566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Balamurugan SS, Bendigeri ND. Community-based study of reproductive tract infections among women of the reproductive age group in the urban health training centre area in Hubli, Karnataka. Indian Journal of Community Medicine. 2012;37(1):34–38. doi: 10.4103/0970-0218.94020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Church DL, Zentner A, Semeniuk H, Henderson E, Read R. Reasons for testing women for genital Chlamydia trachomatis infection in the Calgary region. Canadian Journal of Infectious Diseases. 2003;14(1):35–40. doi: 10.1155/2003/682345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kouri V, Cartaya J, Rodríguez ME, et al. Prevalence of Chlamydia trachomatis in human immunodeficiency virus-infected women in Cuba. Memorias do Instituto Oswaldo Cruz. 2002;97(8):1073–1077. doi: 10.1590/s0074-02762002000800001. [DOI] [PubMed] [Google Scholar]
  • 38.Natividad-Villanueva GU, Santiago E, Manalastas RM, Jr., et al. Human immunodeficiency virus in plasma and cervicovaginal secretions in Filipino women. International Journal of STD and AIDS. 2003;14(12):826–829. doi: 10.1258/095646203322556165. [DOI] [PubMed] [Google Scholar]
  • 39.Seck K, Samb N, Tempesta S, et al. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sexually Transmitted Infections. 2001;77(3):190–193. doi: 10.1136/sti.77.3.190. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES